Immunotherapy for older patients with cancer

被引：4

作者：

Araujo Vargas, Tatianny P. ^{[1
]}

Al-Humiqani, Abdullah ^{[1
,2
]}

Mata, Danilo Giffoni De Mello Morais ^{[1
,2
]}

Menjak, Ines B. ^{[1
,2
,3
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[2] Univ Toronto, Div Med Oncol & Hematol, Dept Med, Toronto, ON, Canada

[3] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr T2, Toronto, ON M4N3M5, Canada

来源：

CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE | 2023年 / 17卷 / 01期

关键词：

cancer; geriatric oncology; immunotherapy; CELL LUNG-CANCER; IMMUNE CHECKPOINT INHIBITORS; ELDERLY-PATIENTS; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; PEMBROLIZUMAB; IPILIMUMAB; ADULTS; CHEMOTHERAPY;

D O I：

10.1097/SPC.0000000000000637

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Purpose of the reviewThe aim of this review is to describe the clinical use and tolerability of immune checkpoint inhibitors in older adults with solid tumors, where there is an abundance of evidence with recent updates including subgroups of older patients. Recent findingsStudies with updated analyses and subgroups of older patients show that in general older patients benefit as well as younger patients and tolerate immunotherapy very well. However, in some instances of combination therapies which may expose patients to more toxicity, the benefits are reduced, and careful selection of older patients, including adjunctive assessments such as geriatric assessment, can help to identify the appropriate treatment for an individual patient. Older adults remain underrepresented in clinical trials, including those involving immunotherapy. Therefore, efforts must be made to include more older patients in trials and to assess real-world evidence to inform decision-making.

引用

页码：37 / 46

页数：10

共 75 条

[21] The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer [J].

Goldstraw, Peter ;

Chansky, Kari ;

Crowley, John ;

Rami-Porta, Ramon ;

Asamura, Hisao ;

Eberhardt, Wilfried E. E. ;

Nicholson, Andrew G. ;

Groome, Patti ;

Mitchell, Alan ;

Bolejack, Vanessa .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) :39-51

[22] A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study [J].

Gomes, F. ;

Lorigan, P. ;

Woolley, S. ;

Foden, P. ;

Burns, K. ;

Yorke, J. ;

Blackhall, F. .

ESMO OPEN, 2021, 6 (01)

[23] Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper [J].

Gomes, Fabio ;

Wong, Melisa ;

Battisti, Nicolo Matteo Luca ;

Kordbacheh, Tiana ;

Kiderlen, Mandy ;

Greystoke, Alastair ;

Luciani, Andrea .

BRITISH JOURNAL OF CANCER, 2020, 123 (06) :874-884

[24] Immunotherapy in older patients with cancer [J].

Granier, C. ;

Gey, A. ;

Roncelin, S. ;

Weiss, L. ;

Paillaud, E. ;

Tartour, E. .

BIOMEDICAL JOURNAL, 2021, 44 (03) :260-271

[25] Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials [J].

Hao, Chunyan ;

Tian, Jinhui ;

Liu, Huiling ;

Li, Fei ;

Niu, Hongxia ;

Zhu, Bingdong .

MEDICINE, 2017, 96 (26)

[26] The development of immunotherapy in older adults: New treatments, new toxicities? [J].

Helissey, Carole ;

Vicier, Cecile ;

Champiat, Stephane .

JOURNAL OF GERIATRIC ONCOLOGY, 2016, 7 (05) :325-333

[27] Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC [J].

Herbst, Roy S. ;

Garon, Edward B. ;

Kim, Dong-Wan ;

Cho, Byoung Chul ;

Gervais, Radj ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Majem, Margarita ;

Forster, Martin D. ;

Monnet, Isabelle ;

Novello, Silvia ;

Gubens, Matthew A. ;

Boyer, Michael ;

Su, Wu-Chou ;

Samkari, Ayman ;

Jensen, Erin H. ;

Kobie, Julie ;

Piperdi, Bilal ;

Baas, Paul .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) :1718-1732

[28] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J].

Herbst, Roy S. ;

Giaccone, Giuseppe ;

de Marinis, Filippo ;

Reinmuth, Niels ;

Vergnenegre, Alain ;

Barrios, Carlos H. ;

Morise, Masahiro ;

Felip, Enriqueta ;

Andric, Zoran ;

Geater, Sarayut ;

Ozguroglu, Mustafa ;

Zou, Wei ;

Sandler, Alan ;

Enquist, Ida ;

Komatsubara, Kimberly ;

Deng, Yu ;

Kuriki, Hiroshi ;

Wen, Xiaohui ;

McCleland, Mark ;

Mocci, Simonetta ;

Jassem, Jacek ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1328-1339

[29] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[30] Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer [J].

Hurria, Arti ;

Mohile, Supriya ;

Gajra, Ajeet ;

Klepin, Heidi ;

Muss, Hyman ;

Chapman, Andrew ;

Feng, Tao ;

Smith, David ;

Sun, Can-Lan ;

De Glas, Nienke ;

Cohen, Harvey Jay ;

Katheria, Vani ;

Doan, Caroline ;

Zavala, Laura ;

Levi, Abrahm ;

Akiba, Chie ;

Tew, William P. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) :2366-U104

← 1 2 3 4 5 6 7 8 →